COMMUNIQUÉS West-GlobeNewswire

Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

15/03/2018 - 21:45

WARREN, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH ) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported [...]

CORRECTING and REPLACING -- BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

15/03/2018 - 21:37

In a release issued under the same headline earlier today by BioDelivery Sciences International, Inc. (NASDAQ: BDSI ), please note that in the second bullet of the Corporate section, the end date of the non-exclusive [...]

Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with 48Hour Discovery

15/03/2018 - 21:30

MINNEAPOLIS, March 15, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT ) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., [...]

Dyadic International Appoints Chief Accounting Officer

15/03/2018 - 21:30

JUPITER, Fla., March 15, 2018 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), today announced that Chief Financial Officer Thomas L. Dubinski  will be on a medical leave of absence, effectively [...]

PLx Pharma Inc. to Discuss 2017 Fourth Quarter and Full Year Financial Results on March 23, 2018 Conference Call

15/03/2018 - 21:30

HOUSTON, March 15, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP ) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 [...]

Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments

15/03/2018 - 21:10

- Achieved Meaningful Progress with Key Clinical Programs - - Anticipate Multiple Data Readouts from SCiStar Study in 2018 into First Quarter of 2019 - - Expect to Enroll First Subject in AST-VAC2 Randomized Clinical [...]

Teligent, Inc. Announces Fourth Quarter and Year End 2017 Results

15/03/2018 - 21:10

BUENA, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT ), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended [...]

OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update

15/03/2018 - 21:05

Acuitas® AMR Gene Panel u5.47 introduced for Research Use Only Fourth quarter revenue consistent with previous year; net loss decreases 38% year over year Conference call begins at 4:30 p.m. Eastern time today [...]

Ovid Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Thursday, March 29, 2018

15/03/2018 - 21:05

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that its [...]

GBT Announces New Employment Inducement Grants

15/03/2018 - 21:05

SOUTH SAN FRANCISCO, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) today announced that on March 12, 2018, the compensation committee of the Company’s board of directors [...]

Checkpoint Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights

15/03/2018 - 21:05

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT ), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and [...]

Cara Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

15/03/2018 - 21:01

STAMFORD, Conn., March 15, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA ), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and [...]

CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update

15/03/2018 - 21:01

Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY ), a clinical-stage biopharmaceutical company focused on developing therapies [...]

Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results

15/03/2018 - 21:01

Conference Call & Live Webcast Today at 4:30pm Eastern Time LIVONIA, Mich., March 15, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP ), a clinical-stage biopharmaceutical company focused on [...]

Rockwell Medical Reports Fourth Quarter and Year End 2017 Results

15/03/2018 - 21:01

Conference call at 4:30 p.m. EDT today WIXOM, Mich., March 15, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI ), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and [...]

Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018

15/03/2018 - 21:01

WEST LAFAYETTE, Ind., March 15, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT ), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that four posters [...]

Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania

15/03/2018 - 21:01

YARDLEY, Pa., March 15, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ: OPTN ), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Optinose was [...]

Interpace Diagnostics Group Reports Fourth Quarter and Full Year 2017 Financial Results, Business Progress Against Plan and Recent Accomplishments

15/03/2018 - 21:01

Revenue for the Quarter Grew 40% over the Comparable Prior Year Quarter and 21% for the Full Year, Raising $30 Million in Equity and Significantly Improving Balance Sheet and Cash Position, Reimbursement Continued to [...]

BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

15/03/2018 - 21:01

Full-year 2017 net revenue of $62.0 million vs. $15.5 million in 2016 BELBUCA ® fourth quarter 2017 net revenue of $9.4 million vs. $6.4 million in third quarter; an increase of 47% BELBUCA prescription growth of 84% in [...]